Zdrowie i gospodarka · 16/07/2026
Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
The National Cancer Institute (NCI) is seeking licensees to commercialize T cell receptor-engineered T cells with hybrid murine/human receptors, which are designed for adoptive cell immunotherapy. These engineered T cells have the potential to selectively expand in the body and target cancer cells.